Table 1. Characteristics of included RCTs.
| Author | Year | ATG/Non-ATG | Disease | Age | Male sex no. (%) | Disease status at transplant no.(%) | Conditioning | Type of ATG | Dose of ATG | Graft source | Donor | Enrollment period | Median follow-up Mo (range) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weiden, PL [26] | 1979 | 29/27 | AL+CML+LLL | 17(1-32) (A) 19(2-47) (N) |
16(55) (A) 19(70) (N) |
CR 13(45) (A), 13(48) (N) Relapse 16(55) (A), 14(52) (N) |
Cy120 mg/kg+10 GyTBI | Horse ATG | 7mg/kg × 6 on alternate days post engraftment (max42 mg/kg; time to engraftment in ATG arm 14-25 days median 18) | BM | MRD | 1976.6-1978.1 | 6~16 |
| Donkey, KC [27] | 1981 | 30/42 | AL+CML+LLL | 19 (2-53) | NR | NR | Cy120 mg/kg+10-15 GyTBI | Horse ATG | 20 mg/kg × 6 alternate days from day + 7 post transplant | BM | MRD | 1978.4-1979.6 | >12 |
| Bacigalupo, A [15] | 2001a | 29/25 | Hematologic malignancies | 28(18-48) (A) 29(13-51) (N) |
NR | CR1/CP 18(62) (A), 15(60) (N) | Cy120 mg/kg+10-15 GyTBI | Rabbit ATG | 3.75 mg/kg on days -4, -3 | BM | MUD | 1995.12-1997.12 | 28.5 (A) 34.7 (N) |
| Bacigalupo, A [15] | 2001b | 27/28 | Hematologic malignancies | 32(14-52) (A) 28(14-46) (N) |
NR | CR1/CP 6(22) (A), 10(36) (N) | Cy120 mg/kg+10-15 Gy TBI | Rabbit ATG | 3.75 mg/kg on days -5, -4, -3, -2 | BM | MUD | 1997.12-2000.7 | 17.7 (A) 18 (N) |
| Champlin, E [28] | 2007 | 70/60 | SAA | 23(1-51) (A) 26(4-51) (N) |
46 (66) (A) 35 (58) (N) |
NR | Cy200 ,mg/kg | Horse ATG | 30 mg/kg on days -5 to -3 | 98% BM | MRD | 1994-2001 | 72 |
| Finke, J [29] | 2009 | 103/98 | AL+CML+MDS | 40 (18-60) (A) 39 (18-60) (N) |
58 (56) (A) 58 (59) (N) |
Early 64(62) (A), 43(43.8) (N) Advanced 39(38) (A), 55(56) (N) |
Bu/Cy 120 mg/kg or Cy 120 mg/kg + TBI 8-12Gy |
Rabbit ATG | 20 mg/kg on days -3, -2, -1 | BM or PBSC | MUD | 2003.5-2007.2 | 48 |
| Bacigalupo, A [30] | 2010 | 84/86 | AL+CML+other | 54%>35 (A) 55%>35 (N) |
Female donor male recipient 10(A), 17(N) | Early 44(52) (A), 45(52) (N) Advanced 40(48) (A), 41(48) (N) |
Cy 120 mg/kg + 12 GyTBI Cy 100 mg/kg + thiotepa 10 mg/kg |
Rabbit ATG | 3.75 mg/kg on days -3, -2 | BM or PBSC | 55% MMUD 15% MMRD 30% MUD |
NR | 43.3(A) 48(N) |
| Kroger, N [16] | 2016 | 83/72 | AL | 39 (18-64) (A) 43.5 (21-61) (N) |
53 (63.9) (A) 40 (55.6) (N) |
CR1 73 (88) (A), 66 (91.7) (N) CR2 10 (12) (N), 6 (8.3) (N) |
Cy 120 mg/kg + 12 GyTBI Cy 120 mg/kg + Bu 16 mg/kg orally or 12.8 mg/kg intravenously, Etoposide 30-60 mg/kg + 12 GyTBI |
Rabbit ATG | 10 mg/kg on days -3, -2, -1 | PBSC | MRD | 2006.12-2012.2 | 24 |
| Walker, I [17] | 2016 | 99/97 | AL+CL+MDS+Lympoma+other | 49 (40-57) (A) 49 (40-56) (N) |
63 (64) (A) 65 (67) (N) |
Early 57 (58) (A), 59 (61) (N) Late 34 (34) (A), 34 (35) (N) Other 8 (8) (A), 4 (4) (N) |
Myeloablative or RIC conditioning | Rabbit ATG | 0.5 mg/kg on day -2, 2.0 mg/kg on day -1, 2.0 mg/kg on day +1 | BM or PBSC | 83% MUD 17% MMUD |
2010.6-2013.8 | 12 |